Abstract
A growing body of evidence shows that tumor necrosis factor (TNF) alpha, a pro-inflammatory cytokine involved in the pathogenesis of rheumatoid arthritis (RA), is also involved in the pathogenesis of reactive and unclassified arthritis. Elevated levels of TNF-alpha and other pro-inflammatory cytokines are seen in these inflammatory arthropathies. The clinical effect on a potential underlying infection is not known, but several studies have suggested at least short-term effectiveness and safety of anti-TNF-alpha therapy in reactive and unclassified arthritis.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antirheumatic Agents / therapeutic use
-
Arthritis / drug therapy*
-
Arthritis / physiopathology*
-
Arthritis, Reactive / drug therapy*
-
Arthritis, Reactive / physiopathology*
-
Etanercept
-
Humans
-
Immunoglobulin G / therapeutic use
-
Immunologic Factors / therapeutic use
-
Infliximab
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
-
Tumor Necrosis Factor-alpha / metabolism*
Substances
-
Antibodies, Monoclonal
-
Antirheumatic Agents
-
Immunoglobulin G
-
Immunologic Factors
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Etanercept